Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
CONCLUSION: PI3K inhibitors had better efficacy than the present standard of concern for patients with breast cancer, especially among patients with PIK3CA mutations. Hence, clinicians and oncologists can provide this drug for the target population with extra caution for diabetes patients.PMID:38275057 | DOI:10.2174/0115680096266181231207110048
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Yi Wang Xianling Du Hongqiang Xin Ruimin Xu Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Diabetes | Endocrinology | Gastroenterology | Study | Toxicology